QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

uniQure N.V. (NASDAQ: QURE) investors who have experienced losses have until April 13, 2026, to apply for the role of lead plaintiff in a securities fraud class action lawsuit. This opportunity allows individuals to represent the class of investors and influence key aspects of the case, including litigation strategy and potential settlements. The court's timeline emphasizes that late applications will not be considered, making it crucial for affected parties to act promptly.

The class action centers around allegations related to uniQure’s Pivotal Study during the class period from September 24, 2025, to October 31, 2025. Specifically, the lawsuit claims that the company inadequately secured FDA approval for the study's design and misrepresented the timeline for its Biologics License Application (BLA) submission. Following a public disclosure by uniQure on November 3, 2025, where they indicated a shift in the FDA's stance on the sufficiency of Phase I/II study data, the company’s stock plummeted nearly 49%—falling from $67.69 to $34.29 per share in a single trading session.

Investors who believe they qualify as affected parties or possess relevant information are encouraged to reach out to Lauren Molinaro at Kirby McInerney LLP, who is handling these inquiries free of charge. The firm is known for its extensive experience in securities litigation and has secured billions for shareholders over the years. Interested investors can contact them via email or their website for further information or to join the action.

As this case progresses, it underscores the importance of investors staying vigilant about corporate disclosures and understanding their rights in the face of potential securities fraud.

Investors in uniQure N.V. (NASDAQ: QURE) should closely monitor developments related to the ongoing class action lawsuit tied to significant share price fluctuations. The lawsuit concerns alleged securities fraud, primarily linked to the company's Pivotal Study for AMT-130, which did not receive full FDA approval. Following a disclosure on November 3, 2025, regarding uncertainties surrounding the FDA's stance on the data adequacy for the Biologics License Application (BLA), uniQure's stock plummeted nearly 50%, raising concerns about the company's transparency and future regulatory challenges.

For investors who believe they have suffered financial losses during the class period from September 24, 2025, to October 31, 2025, the firm Kirby McInerney LLP recommends participating as a lead plaintiff by filing your application by the April 13, 2026 deadline. Engaging in this litigation could provide insights and potential compensation, given that courts typically appoint individual investors over institutions as lead plaintiffs.

As you navigate this turbulent situation, consider a few key strategies:

1. **Assessment of Financial Exposure**: Review your investment in uniQure to evaluate your loss. Given the drastic price drop, it may be worth consulting a financial advisor about your position and risk tolerance before making further investment decisions.

2. **Staying Informed**: Keeping abreast of court proceedings can provide a clearer picture of potential outcomes. Litigation can take time, and the course of the lawsuit might influence share prices and public sentiment.

3. **Diversification and Risk Management**: If uniQure constitutes a large percentage of your portfolio, this could be an opportune moment to reassess your exposure. A diversified portfolio may help mitigate the risks associated with individual stocks, particularly those entangled in legal disputes.

In conclusion, while the upcoming legal proceedings may present a path to recovery for some investors, ongoing market volatility requires prudent management and informed decision-making.